EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH
(EEJSAR) ISSN: 2992-4146
©EEJSAR Publications Volume 7 Issue 3 2025



# Harnessing Immunomodulatory Therapies in Neonates: Achieving Immune Tolerance without Immunosuppression

**Odile Patrick Thalia**

**Faculty of Biological Sciences Kampala International University Uganda**

## ABSTRACT

The neonatal period represents a critical window in immune development, where the balance between immune activation and tolerance determines long-term health trajectories. During this stage, the immune system is undergoing rapid maturation, establishing foundational responses to pathogens while simultaneously learning to tolerate self-antigens and benign environmental exposures such as food proteins and commensal microbiota. Disruptions in this delicate balance may predispose individuals to allergic, autoimmune, and inflammatory diseases later in life. Immunomodulatory therapies administered during this early phase have the potential to shape immune programming in ways that foster durable tolerance while preserving protective immunity. Unlike traditional immunosuppressive approaches, these strategies aim to recalibrate immune responses, promoting regulatory mechanisms without undermining the body's capacity to defend against infections. Such interventions could not only prevent the onset of immune-mediated diseases but also reduce the long-term burden of chronic illnesses that stem from immune dysregulation. This article reviews the underlying mechanisms that facilitate immune tolerance in neonates, highlights current and emerging immunomodulatory strategies designed for early-life application, and discusses the clinical implications, challenges, and future directions for optimizing these therapies. As the field of neonatal immunotherapy advances, precision approaches that harness early-life immune plasticity may redefine preventive medicine and pediatric care.

**Keywords:** Neonatal immune tolerance, Immune programming, Immunomodulatory therapies, Early-life interventions, Preventive immunotherapy

## INTRODUCTION

The neonatal period is characterized by a unique immunological landscape that reflects the physiological necessity to balance immune activation and regulation [1]. The immune system of the neonate, while capable of responding to infectious threats, is distinct from that of older children and adults. It is developmentally programmed to be more permissive and tolerogenic, a feature essential for maintaining harmony with maternal antigens encountered in utero, and for establishing symbiotic relationships with commensal microbiota postnatally [2]. This state of immune tolerance is not a flaw but a crucial adaptation that promotes survival in early life. From birth, the neonate is exposed to a rapidly changing antigenic environment, including dietary proteins, microbes, and airborne allergens [3]. In this context, the immune system must learn to distinguish between harmful and harmless stimuli [4]. While this environment provides opportunities for immune education, it also presents risks—namely, the potential for inappropriate immune responses that could lead to chronic allergic or autoimmune conditions [5].

Immunomodulatory therapies that intervene during this early period of immune plasticity hold considerable promise. By guiding immune development along regulatory pathways, these strategies aim to prevent the onset of diseases driven by immune dysregulation [6]. Importantly, this must be achieved without suppressing the neonate's ability to combat infections, which remains a leading cause of morbidity and mortality in this age group [7]. Therefore, a nuanced understanding of neonatal immune ontogeny, the factors that influence immune trajectory, and the window of therapeutic opportunity is essential for the rational design of safe and effective interventions.

### The Neonatal Immune System: Tolerogenic by Design

The neonatal immune system is uniquely adapted to tolerate rather than attack [8]. This tolerogenic bias is reflected across both innate and adaptive immune compartments. Neonates display a high frequency of regulatory T cells

(Tregs), which play a central role in suppressing immune activation and maintaining homeostasis [9]. These cells are particularly effective at modulating responses to self-antigens and preventing the onset of autoimmunity [10]. Antigen-presenting cells (APCs), such as dendritic cells and macrophages, also exhibit reduced maturation and co-stimulatory capacity in neonates [11]. This phenotype contributes to impaired T-cell activation but favors the development of tolerance [12]. Additionally, neonatal T cells are more likely to differentiate into Th2 cells, which are associated with anti-inflammatory responses, rather than Th1 cells, which drive inflammation and cytotoxic activity [13].



Humoral immunity in neonates is influenced by maternal antibodies transferred transplacentally and through breastfeeding [14]. While these antibodies offer passive protection, they can also suppress the neonate's own antibody responses, contributing to a transient window of immunological vulnerability [15]. Nevertheless, this phase allows for the shaping of immune memory in response to low-dose or non-threatening antigens. The neonatal period is also a critical time for microbial colonization, particularly of the gut [16]. The establishment of a healthy microbiota has been shown to play an essential role in immune system calibration, promoting the development of tolerogenic dendritic cells and the expansion of regulatory lymphocyte populations [17]. Interruption of this process, for instance by cesarean delivery or early antibiotic use, has been associated with increased risk of allergic and autoimmune diseases [18].

Given this background, the design of immunomodulatory therapies in neonates must account for the unique features of the developing immune system. Strategies should aim to reinforce tolerance mechanisms while simultaneously priming the immune system to respond appropriately to pathogens [19]. This delicate balance is the cornerstone of neonatal immunotherapy aimed at achieving immune tolerance without compromising host defense.

## Immunomodulatory Strategies to Induce Tolerance Without Suppression

Inducing immune tolerance during early life without compromising overall immune competence is a key goal in neonatal immunotherapy. Such strategies aim to recalibrate immune responses toward regulatory and homeostatic pathways, reducing the risk of allergy, autoimmunity, and chronic inflammation while maintaining the ability to respond to pathogens and vaccines [20]. Recent approaches emphasize the selective promotion of regulatory T cells (Tregs), modulation of antigen-presenting cells, and shaping of the mucosal environment to favor immunological tolerance [21].

## Probiotics and Microbiota-Based Therapies

The neonatal gut microbiota plays a central role in immune system maturation. Probiotic supplementation during infancy—particularly with strains like *Lactobacillus rhamnosus*, *Bifidobacterium infantis*, and *Lactobacillus casei*—has been shown to enhance epithelial barrier integrity and promote the expansion of Tregs and tolerogenic dendritic cells (DCs) [22]. These microbial signals stimulate the production of anti-inflammatory cytokines like IL-10 and TGF-β, creating a regulatory milieu within the gut-associated lymphoid tissue [23]. Emerging strategies include fecal microbiota transplantation (FMT) from healthy donors and postbiotic administration, both of which aim to restore or establish a microbiota composition that favors immune tolerance and reduces the incidence of atopic and autoimmune conditions [24].

## Antigen-Specific Immunotherapy

Oral and transdermal antigen delivery in early life is being explored to induce immune tolerance to allergens and autoantigens [25]. Administering low doses of allergens such as peanut or egg protein during critical windows of immune development promotes the generation of antigen-specific Tregs, leading to suppression of hypersensitivity reactions [26]. Similarly, tolerogenic vaccination approaches involving autoantigens (e.g., insulin peptides in type 1 diabetes) aim to prevent the onset of autoimmunity without systemic immunosuppression [27]. These interventions leverage the concept of oral tolerance and the tolerogenic potential of skin-resident antigen-presenting cells to establish durable immune regulation [28].

## Adjuvants and TLR Agonists

Selective activation of pattern recognition receptors like Toll-like receptors (TLRs) offers a means to shape early immune responses. TLR agonists derived from components such as BCG (TLR2/4) or synthetic CpG oligodeoxynucleotides (TLR9) can promote innate immune training while skewing adaptive responses toward a regulatory profile [29]. These adjuvants stimulate IL-10-producing cells and foster a balanced Th1/Th2 response, mitigating overactivation and fostering immune resilience [30].

## Cytokine-Based Modulation

Targeted cytokine therapies offer precise tools to bolster tolerance mechanisms [31]. Low-dose IL-2 preferentially expands Tregs without stimulating effector T cells. IL-10 and TGF-β analogs or inducers help maintain an anti-inflammatory environment, enhance Treg function, and promote immune resolution [32]. These cytokine-based strategies avoid the global immunosuppression seen with traditional anti-inflammatory drugs [33].

## Epigenetic and Metabolic Interventions

Long-lasting immune tolerance requires stable regulatory cell phenotypes, which can be supported by epigenetic and metabolic reprogramming [34]. Agents that modulate DNA methylation (e.g., DNMT inhibitors) or histone acetylation (e.g., HDAC inhibitors) can upregulate FoxP3 and other tolerance-associated genes [35,36]. Similarly, interventions targeting metabolic pathways—such as enhancing fatty acid oxidation or mTOR inhibition—promote Treg survival and suppress effector T cell differentiation [37]. These approaches represent a frontier in non-immunosuppressive, long-term immune modulation

## Clinical Applications and Disease Prevention

Immunomodulatory therapies in neonates are emerging as transformative approaches for preventing and mitigating a range of chronic and immune-mediated conditions [38]. Early-life interventions aim to shape the developing immune system toward a state of tolerance and resilience, offering protective effects that extend well into later life. One of the most promising areas of application is the **prevention of allergic diseases**, including atopic dermatitis, asthma, and food allergies [39]. By modulating immune responses during the neonatal period—a critical window of immune plasticity—therapies such as probiotic supplementation, microbial-derived immunomodulators, and early antigen exposure strategies have shown potential in reducing hypersensitivity reactions and promoting immune tolerance [40].

Similarly, autoimmune disorders like type 1 diabetes and juvenile idiopathic arthritis are increasingly being linked to dysregulation in early immune development [41]. Neonatal immunotherapy approaches, such as antigen-specific tolerance induction or T-regulatory cell modulation, may reduce the risk of autoimmune pathology by preventing the aberrant immune activation that characterizes these diseases [42]. Another significant clinical application lies in pediatric transplantation, where immunomodulatory interventions are being investigated to reduce the risk of graft rejection and graft-versus-host disease (GVHD) [43]. Strategies that induce immune tolerance without broad immunosuppression—such as regulatory T-cell therapies or tolerogenic dendritic cells—could improve transplant outcomes while minimizing the burden of lifelong immunosuppressive treatment [44]. Overall, these applications highlight the potential of neonatal immunomodulation to not only treat but also *prevent* immune-related diseases, setting a new paradigm in pediatric care.

## Challenges and Research Gaps

Despite encouraging progress, several critical challenges and knowledge gaps hinder the widespread clinical adoption of neonatal immunomodulatory therapies. The foremost concern is long-term safety and efficacy [45]. While short-term results are often promising, few studies extend into adolescence or adulthood. There is an urgent need for robust longitudinal trials to assess the durability of induced tolerance and to monitor for delayed adverse effects.

Biomarker development is another pressing gap [46]. Reliable and non-invasive biomarkers are essential to predict individual responses, monitor therapeutic efficacy, and guide personalized treatment protocols. Interindividual variability presents a complex challenge [47]. Genetic predispositions, epigenetic modifications, perinatal exposures, and environmental factors can all modulate the outcomes of immunotherapy, necessitating a precision medicine approach. Finally, ethical considerations must be addressed, particularly regarding informed consent in neonates, equitable access to therapies, and the ethical justification for immunological interventions in otherwise healthy infants [48]. These factors demand careful evaluation as the field advances toward clinical translation

## Future Directions

The future of neonatal immunomodulatory therapies lies in the integration of cutting-edge technologies with an improved understanding of immune ontogeny. Advances in systems immunology are enabling comprehensive profiling of neonatal immune responses, uncovering dynamic patterns of cellular and molecular signaling that can guide precise therapeutic targeting. Artificial intelligence (AI) and machine learning are increasingly being applied to large-scale immunological datasets, allowing for the identification of predictive biomarkers, therapeutic response patterns, and personalized intervention strategies.

A key priority for future research is identifying the optimal timing, dosage, and combinations of immunomodulatory interventions. Given the critical windows of immune development in early life, understanding when and how to intervene is essential for maximizing benefits while minimizing risks. Additionally, the development of multifunctional vaccine platforms that simultaneously promote protective immunity and immune tolerance is a promising avenue. These platforms may integrate adjuvants, antigens, and regulatory elements in a manner tailored to the neonatal immune landscape. Another crucial direction involves ensuring equitable access to these advanced therapies, especially in low-resource settings, where the burden of immune-mediated diseases is disproportionately high. Scalable, cost-effective strategies that account for local environmental and genetic factors must be prioritized to avoid widening global health disparities.

## CONCLUSION

Neonatal immunomodulatory therapies represent a paradigm shift in pediatric medicine, offering the potential to promote immune tolerance without inducing immunosuppression. By harnessing the unique plasticity of the developing immune system, these interventions can fundamentally alter disease risk trajectories, decreasing the incidence of allergies, autoimmunity, and transplant complications. As scientific and technological innovations continue to evolve, it is imperative to pursue robust research, ethical oversight, and global collaboration to ensure these therapies are safe, effective, and accessible. The future lies in a proactive, personalized, and equitable approach to early-life immune programming that safeguards health across the lifespan.



## REFERENCES


1. Doherty TM, Hu A, Salik I. Physiology, neonatal. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539840/
2. Nunez N, Réot L, Menu E. Neonatal immune system ontogeny: the role of maternal microbiota and associated factors. How might the Non-Human Primate model enlighten the path? Vaccines. 2021;9(6):584. doi:10.3390/vaccines9060584
3. Pierau M, Arra A, Brunner-Weinzierl MC. Preventing atopic diseases during childhood – early exposure matters. Frontiers in Immunology. 2021;12. doi:10.3389/fimmu.2021.617731
4. Nicholson LB. The immune system. Essays in Biochemistry. 2016;60(3):275–301. doi:10.1042/ebc20160017
5. Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Autoimmune responses are directed against self antigens. Immunobiology - NCBI Bookshelf. 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27155/
6. National Academies Press (US). Promising approaches to the development of immunomodulation for the treatment of infectious diseases. Treating Infectious Diseases in a Microbial World - NCBI Bookshelf. 2006. Available from: https://www.ncbi.nlm.nih.gov/books/NBK19846/
7. Singh M, Alsaleem M, Gray CP. Neonatal sepsis. StatPearls - NCBI Bookshelf. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531478/
8. Weng J, Couture C, Girard S. Innate and adaptive immune systems in physiological and pathological pregnancy. Biology. 2023;12(3):402. doi:10.3390/biology12030402
9. Hayakawa S, Ohno N, Okada S, Kobayashi M. Significant augmentation of regulatory T cell numbers occurs during the early neonatal period. Clinical & Experimental Immunology. 2017;190(2):268–79. doi:10.1111/cei.13008
10. Yasmeen F, Pirzada RH, Ahmad B, Choi B, Choi S. Understanding autoimmunity: mechanisms, predisposing factors, and cytokine therapies. International Journal of Molecular Sciences. 2024;25(14):7666. doi:10.3390/ijms25147666
11. Cheng H, Chen W, Lin Y, Zhang J, Song X, Zhang D. Signaling pathways involved in the biological functions of dendritic cells and their implications for disease treatment. Molecular Biomedicine. 2023;4(1). doi:10.1186/s43556-023-00125-3
12. Nurieva R, Wang J, Sahoo A. T-cell tolerance in cancer. Immunotherapy. 2013;5(5):513–31. doi:10.2217/imt.13.33
13. Zaghouani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends in Immunology. 2009;30(12):585–91. doi:10.1016/j.it.2009.09.002
14. Niewiesk S. Maternal Antibodies: Clinical Significance, Mechanism of Interference with Immune Responses, and Possible Vaccination Strategies. Frontiers in Immunology. 2014;5. doi:10.3389/fimmu.2014.00446
15. Edwards KM. Maternal antibodies and infant immune responses to vaccines. Vaccine. 2015;33(47):6469–72. doi:10.1016/j.vaccine.2015.07.085
16. Sanidad KZ, Zeng MY. Neonatal gut microbiome and immunity. Current Opinion in Microbiology. 2020;56:30–7. doi:10.1016/j.mib.2020.05.011
17. Shvets Y, Khranovska N, Senchylo N, Ostapchenko D, Tymoshenko I, Onysenko S, et al. Microbiota substances modulate dendritic cells activity: A critical view. Heliyon. 2024;10(5):e27125. doi:10.1016/j.heliyon.2024.e27125
18. Dera N, Kosińska-Kaczyńska K, Żeber-Lubecka N, Brawura-Biskupski-Samaha R, Massalska D, Szymusik I, et al. Impact of Early-Life microbiota on immune system development and allergic disorders. Biomedicines. 2025;13(1):121. doi:10.3390/biomedicines13010121
19. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science. 2012;335(6071):936–41. doi:10.1126/science.1214935
20. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Review of Clinical Immunology. 2014;10(9):1171–84. doi:10.1586/1744666x.2014.942288

21. Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, et al. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges. Human Vaccines & Immunotherapeutics. 2022;18(1). doi:10.1080/21645515.2022.2035117
22. Javanshir N, Hosseini GNG, Sadeghi M, Esmaeili R, Satarikia F, Ahmadian G, et al. Evaluation of the Function of Probiotics, Emphasizing the Role of their Binding to the Intestinal Epithelium in the Stability and their Effects on the Immune System. Biological Procedures Online. 2021;23(1). doi:10.1186/s12575-021-00160-w
23. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity. Current Opinion in Pharmacology. 2009;9(4):447–53. doi:10.1016/j.coph.2009.04.008

24. Karimi M, Shirsalimi N, Hashempour Z, Omran HS, Sedighi E, Beigi F, et al. Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: a comprehensive literature review. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1439176
25. Zhao J, He P, Jiang M, He C, Zhao Y, Zhang Z, et al. Transdermally delivered tolerogenic nanoparticles induced effective immune tolerance for asthma treatment. Journal of Controlled Release. 2024;366:637–49. doi:10.1016/j.jconrel.2024.01.018
26. Benedé S, Blázquez AB, Chiang D, Tordesillas L, Berin MC. The rise of food allergy: Environmental factors and emerging treatments. EBioMedicine. 2016;7:27–34. doi:10.1016/j.ebiom.2016.04.012
27. Zhou X, Zhang S, Yu F, Zhao G, Geng S, Yu W, et al. Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model. Human Vaccines & Immunotherapeutics. 2019;16(2):240–50. doi:10.1080/21645515.2019.1616504
28. Arve-Butler S, Moorman CD. A comprehensive overview of tolerogenic vaccine adjuvants and their modes of action. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1494499
29. Luchner M, Reinke S, Milicic A. TLR agonists as vaccine adjuvants targeting cancer and infectious diseases. Pharmaceutics. 2021;13(2):142. doi:10.3390/pharmaceutics13020142
30. Kayesh MEH, Kohara M, Tsukiyama-Kohara K. TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1249718
31. Fu Y, Tang R, Zhao X. Engineering cytokines for cancer immunotherapy: a systematic review. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1218082
32. Zhang JY, Hamey F, Trzupek D, Mickunas M, Lee M, Godfrey L, et al. Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes. Nature Communications. 2022;13(1). doi:10.1038/s41467-022-34162-3
33. Adorini L. Cytokine-based immunointervention in the treatment of autoimmune diseases. Clinical & Experimental Immunology. 2003;132(2):185–92. doi:10.1046/j.1365-2249.2003.02144.x
34. Lu J, Liang Y, Meng H, Zhang A, Zhao J, Zhang C. Metabolic controls on epigenetic reprogramming in regulatory T cells. Frontiers in Immunology. 2021;12. doi:10.3389/fimmu.2021.728783
35. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009;114(18):3727–35. doi:10.1182/blood-2009-05-219584
36. Kim Y, Wang SE, Jiang YH. Epigenetic therapy of Prader–Willi syndrome. Translational Research. 2019;208:105–18. doi:10.1016/j.trsl.2019.02.012
37. Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Molecular Cell. 2020;78(6):1019–33. doi:10.1016/j.molcel.2020.05.034
38. Schüller SS, Kramer BW, Villamor E, Spittler A, Berger A, Levy O. Immunomodulation to prevent or treat neonatal sepsis: past, present, and future. Frontiers in Pediatrics. 2018;6. doi:10.3389/fped.2018.00199
39. Pierau M, Arra A, Brunner-Weinzierl MC. Preventing atopic diseases during childhood – early exposure matters. Frontiers in Immunology. 2021;12. doi:10.3389/fimmu.2021.617731
40. Jain N. The early life education of the immune system: Moms, microbes and (missed) opportunities. Gut Microbes. 2020;12(1):1824564. doi:10.1080/19490976.2020.1824564
41. Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 Diabetes mellitus and Autoimmune Diseases: A Critical review of the Association and the application of Personalized Medicine. Journal of Personalized Medicine. 2023;13(3):422. doi:10.3390/jpm13030422
42. Kenison JE, Stevens NA, Quintana FJ. Therapeutic induction of antigen-specific immune tolerance. Nature Reviews Immunology. 2023;24(5):338–57. doi:10.1038/s41577-023-00970-x
43. Flinn AM, Gennery AR. Recent advances in graft-versus-host disease. Faculty Reviews. 2023;12. doi:10.12703/r/12-4

44. Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, et al. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1372862
45. Paton MCB, Benders M, Blatch-Williams R, Dallimore E, Edwards A, Elwood N, et al. Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024). Pediatric Research. 2025. doi:10.1038/s41390-025-03856-x
46. Llitjos JF, Carrol ED, Osuchowski MF, Bonneville M, Scicluna BP, Payen D, et al. Enhancing sepsis biomarker development: key considerations from public and private perspectives. Critical Care. 2024;28(1). doi:10.1186/s13054-024-05032-9
47. Linakis MW, Roberts JK, Lala AC, Spigarelli MG, Medlicott NJ, Reith DM, et al. Challenges Associated with Route of Administration in Neonatal Drug Delivery. Clinical Pharmacokinetics. 2015;55(2):185–96. doi:10.1007/s40262-015-0313-z
48. Krishna S, Fuloria M. Ethical considerations in neonatal research. NeoReviews. 2022;23(3):e151–8. doi:10.1542/neo.23-3-e151



**CITE AS: Odile Patrick Thalia (2025). Harnessing Immunomodulatory Therapies in Neonates: Achieving Immune Tolerance without Immunosuppression. EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH, 7(3):114-119**